{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:04:36Z","timestamp":1789358676850,"version":"build-2803163510"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1097\/inf.0000000000005403","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:00:24Z","timestamp":1789358424000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Way Forward With Pertussis Vaccination"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4950-7016","authenticated-orcid":false,"given":"Stanley A.","family":"Plotkin","sequence":"first","affiliation":[{"name":"Emeritus Professor of Pediatrics, University of Pennsylvania, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"R1-20260914","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm6903a5","article-title":"Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the advisory committee on immunization practices\u2014United States, 2019.","volume":"69","author":"Havers","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R2-20260914","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12879-020-4824-3","article-title":"Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review.","volume":"20","author":"Vygen-Bonnet","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R3-20260914","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3390\/vaccines10121990","article-title":"Vaccination in pregnancy against pertussis: a consensus statement on behalf of the global pertussis initiative.","volume":"10","author":"Abu-Raya","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R4-20260914","doi-asserted-by":"crossref","first-page":"e2023062664","DOI":"10.1542\/peds.2023-062664","article-title":"Maternal pertussis vaccination, infant immunization, and risk of pertussis.","volume":"152","author":"Regan","year":"2023","journal-title":"Pediatrics"},{"key":"R5-20260914","doi-asserted-by":"crossref","first-page":"101211","DOI":"10.1016\/j.lanmic.2025.101211","article-title":"Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.","volume":"6","author":"Gbesemete","year":"2025","journal-title":"Lancet Microbe"},{"key":"R6-20260914","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41541-026-01443-7","article-title":"BPZE1 vaccination induces IL-17+ and IL-22+ CD4+ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation.","volume":"11","author":"Hill","year":"2026","journal-title":"NPJ Vaccines"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:00:25Z","timestamp":1789358425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":6,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005403","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}